Semax vs Selank: Nootropic Peptide Comparison

Semax and Selank are two synthetic peptides developed in Russia with distinct cognitive and neurological effects. While both are classified as nootropics, they target different neurological pathways and serve different research applications.

Overview

Mechanism Comparison

Semax: The Cognitive Enhancer

Semax works through several interconnected pathways:

1. BDNF upregulation — Increases brain-derived neurotrophic factor expression in the hippocampus and cortex, promoting neuroplasticity and memory formation.

2. Dopaminergic modulation — Influences dopamine signaling in the prefrontal cortex, improving attention, motivation, and executive function.

3. Neuroprotection — Reduces oxidative stress and inflammation in neural tissue. Studied for post-stroke recovery in clinical settings.

4. Gene expression — Modulates expression of genes involved in immune function and neurogenesis.

Selank: The Anxiolytic

Selank targets different neurological systems:

1. GABAergic modulation — Enhances GABA signaling, the brain’s primary inhibitory neurotransmitter system. This underlies its anxiolytic (anti-anxiety) effects.

2. BDNF regulation — Also influences BDNF, but through different mechanisms than Semax. Effects on neuroplasticity are more subtle.

3. Immune modulation — As a tuftsin analog, Selank has immunomodulatory properties that may indirectly support cognitive function through reduced neuroinflammation.

4. Enkephalin stabilization — Prevents degradation of endogenous enkephalins, contributing to its mood-stabilizing effects.

Evidence Comparison

Semax Clinical Data

Semax is approved in Russia and has been studied in:

• Post-stroke recovery — Multiple clinical trials showing improved cognitive outcomes after ischemic stroke
• Cognitive decline — Studies in age-related cognitive impairment showing attention and memory improvements
• Glaucoma — Approved for optic nerve protection
• ADHD symptoms — Preliminary data on attention and focus improvement

Selank Clinical Data

Selank is approved in Russia for anxiety disorders:

• Generalized anxiety disorder — Clinical trials demonstrating anxiolytic effects comparable to benzodiazepines without sedation
• Cognitive function under stress — Maintained cognitive performance during stress conditions
• Immune function — Immunomodulatory effects in clinical settings
• Learning and memory — Modest improvements in animal models

Effects Comparison

Safety Comparison

Both peptides have favorable safety profiles based on clinical use in Russia:

• No significant side effects reported in clinical trials
• No addiction or dependence potential (unlike benzodiazepines for Selank’s use case)
• No withdrawal effects
• Intranasal administration is well-tolerated
• Limited long-term safety data outside of Russian clinical use

Which Should You Choose?

Choose Semax if studying:

• Cognitive enhancement and focus
• Post-stroke neuroprotection
• Attention deficit applications
• BDNF-mediated neuroplasticity
• Dopaminergic cognitive pathways

Choose Selank if studying:

• Anxiety disorders
• Stress resilience
• Immune-cognitive interactions
• GABAergic modulation
• Mood stabilization without sedation

Consider both when studying comprehensive cognitive support, as they address different aspects — Semax for performance, Selank for stability under stress.

Related Research

• NAD+ Research Guide — cellular energy and neuroprotection
• BPC-157 Research Guide — neuroprotective mechanisms
• Selank Mechanism — detailed GABAergic mechanism
• Semax Mechanism — detailed BDNF pathway